MRIGlobal Engages Industry Expert in Expansion of Molecular Diagnostic Division
Mary E. Holland Lends Broad Experience in Commercialization of Molecular Diagnostics with Corporate Partners.
KANSAS CITY, Mo., Sept. 9, 2013 /PRNewswire-USNewswire/ -- MRIGlobal today announced that it is working with Mary E. Holland as part of its continuing expansion of its Molecular Diagnostics Division, which helps commercial diagnostics developers get their products to market faster.
Holland brings years of experience in creating and expanding market segments in Clinical Molecular Diagnostics, with a focus on the development and marketing of core product lines for clinical reference laboratories and diagnostic product manufacturers. She will work closely with Maureen Thornton, Head of Global Business Development for MRIGlobal Molecular Diagnostics, and Meeta Patnaik, M.D.
Holland has served in multiple leadership roles, playing a key role in solidifying brand and product awareness as well as driving profits for multiple companies that went public or to a merger/acquisition by Fortune 500 companies.
She most recently served as Vice President of Sales and Marketing with Madison, Wisconsin-based EraGen Biosciences, now part of Luminex; prior to that she played an integral role in launching Third Wave Technologies. As an entrepreneur, she co-founded Oncogenetics Inc., a comprehensive cancer diagnostic reference laboratory.
"Mary Holland brings diverse and highly relevant experience to the MRIGlobal Molecular Diagnostics Team," said Michael Cassler, Ph.D., Director of MRIGlobal Diagnostics. "She will help increase our service offering to a broader customer base and further our continued expansion into the commercial diagnostics sector, a priority for our business. We are both excited and fortunate to have someone of Mary's caliber working for us as a key member of our team."
MRIGlobal Molecular Diagnostics is a division of MRIGlobal, established in 1944 as Midwest Research Institute. MRIGlobal is based in Kansas City, Mo., operates in nine states and Washington, D.C. MRIGlobal employs more than 500 and manages 2,600-plus workers through management and operations programs with government clients.
MRIGlobal's Diagnostics Division provides assay development for menu expansion in in vitro and molecular diagnostics, validation and clinical testing, sample access and reference material, and platform engineering and integration. MRIGlobal operates a Clinical Laboratory Improvement Amendments (CLIA)-laboratory accredited by the College of American Pathologists. MRIGlobal is ISO 9001 certified and employs current Good Manufacturing Practices and Good Laboratory Practices, and maintains Biosafety Level 3 laboratories.
For more information, visit www.mriglobal.org/diagnostics.